MAP BioPharma

The changes which have been proposed to the way that NICE appraises new treatments could potentially see cost effective treatments reaching patients almost three months earlier than they currently do, reports NHS England.

Treatments with a cost per QALY of £10,000 or less would be fast tracked and dealt with under a “light touch process”.